Nikolaos Andreatos, MD, on Adverse Events Following Radiotherapy and Immunotherapy in Patients With Melanoma and Merkel Cell Carcinoma

Posted: Tuesday, June 30, 2020

Nikolaos Andreatos, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses data from a preliminary report of an evolving retrospective registry, which showed that almost half of patients with melanoma and Merkel cell carcinoma developed new immune-related adverse events following radiotherapy, a quarter of whom require hospitalization. These rates raise concern about the additive toxicity of immune checkpoint inhibitors plus radiotherapy.